Platelets and lipoprotein(a) in retinal vein occlusion: Mutual targets for aspirin therapy [6]

Thrombosis and Haemostasis

Volumn 97, Issue 6, 2007, Pages 1059-1060

  Lippi, Giuseppe ^a   Franchini, Massimo ^b   Targher, Giovanni ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LIPOPROTEIN;

ARGON LASER; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DECOMPRESSION SURGERY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LASER COAGULATION; LETTER; LIPOPROTEIN BLOOD LEVEL; PATHOGENESIS; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; RETINA VEIN OCCLUSION; RISK ASSESSMENT; RISK FACTOR; SURGICAL TECHNIQUE; THROMBOCYTE ACTIVATION; THROMBOSIS; TREATMENT INDICATION; VASCULAR SURGERY; VITRECTOMY;

APOLIPOPROTEINS A; ASPIRIN; BLOOD PLATELETS; HUMANS; LIPOPROTEIN(A); PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RETINAL VEIN OCCLUSION;

EID: 34250636276     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-02-0108     Document Type: Letter

References (32)

1. Fateh-Moghadam S, Gawaz M. Retinal vein occlusion disease and platelet activation: Will antiplatelet therapy be a promising therapeutic strategy for patients with retinal vein occlusion disease in the future? Thromb Haemost 2007; 97: 169-170.
2. Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002; 32: 308-311.
3. Mandell MA, Sharma S. Ophthaproblem. Central retinal vein obstruction. Can Fam Physician 2005; 51: 1627.
4. Shahid H, Hossain P, Amoaku WM. The management of retinal vein occlusion: is interventional ophthalmology the way forward? Br J Ophthalmol 2006; 90: 627-639.
5. Mester U. Surgical approach to retinal vein occlusion. Klin Monatsbl Augenheilkd 2005; 222: 299-308.
6. Shahid H, Hossain P, Amoaku WM. The management of retinal vein occlusion: is interventional ophthalmology the way forward? Br J Ophthalmol 2006; 90: 627-639.
7. Walsh PN, Goldberg RE, Tax RL, et al. Platelet coagulant activities and retinal vein thrombosis. Thromb Haemost 1977; 38: 399-406.
8. Leoncini G, Bruzzese D, Signorello MG, et al. Platelet activation by collagen is increased in retinal vein occlusion. Thromb Haemost 2007; 97: 218-227.
9. Mansour AM, Walsh JB, Henkind P. Central retinal vein occlusion and diabetes mellitus. Thromb Haemost 1987; 58: 1088.
10. Albisinni R, Coppola A, Loffredo M, et al. Retinal vein occlusion and inherited conditions predisposing to thrombophilia. Thromb Haemost 1998; 80: 702-703.
11. Prisco D, Bertini L, Marcucci R, et al. Retinal vein occlusions: diseases for the internist? Ann Ital Med Int 2000; 15: 75-84.
12. Marcucci R, Bertini L, Giusti B, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001; 86: 772-776.
13. Janssen MC, den Heijer M, Cruysberg JR, et al. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? A meta-analysis of thrombophilic factors. Thromb Haemost 2005; 93: 1021-1026.
14. Meschengieser SS. Retinal vein occlusion: a venous complication in an "arterial" patient? Thromb Haemost 2005; 93: 1013.
15. Arsene S, Delahousse B, Regina S, et al. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost 2005; 94: 101-106.
16. Linna T, Ylikorkala A, Kontula K, et al. Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 1997; 77: 214-216.
17. D'Angelo A, Tavola A, Fermo I, et al. Moderate hyperhomocysteinemia and central retinal vein occlusion. Thromb Haemost 2002; 87: 1078-1079.
18. Gori AM, Marcucci R, Fatini C, et al. Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. Thromb Haemost 2004; 92: 54-60.
19. Lippi G, Guidi G: Lipoprotein(a): an emerging cardiovascular risk factor. Crit Rev Clin Lab Sci 2003; 40: 1-42.
20. Miles LA, Plow EF. Lp(a): an interloper into the fibrinolytic system? Thromb Haemost 1990; 63: 331-335.
21. Bandello F, Vigano D'Angelo S, Parlavecchia M, et al. Hypercoagulability and high lipoprotein(a) levels in patients with central retinal vein occlusion. Thromb Haemost 1994; 72: 39-43.
22. Lip PL, Blann AD, Jones AF, et al. Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye 1998; 12: 245-251.
23. Murata M, Saito T, Takahashi S, et al. Plasma lipoprotein(a) levels are high in patients with central retinal artery occlusion. Thromb Res 1998; 91: 169-175.
24. Ribeaudeau-Saindelle F, Glacet-Bernard A, Lelong F, et al. Retinal vein occlusion and lipoprotein (a). J Fr Ophtalmol 1998; 21: 245-250.
25. Glueck CJ, Bell H, Vadlamani L, et al. Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol 1999; 117: 43-49.
26. Wong TY, Larsen EK, Klein R, et al. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. Ophthalmology 2005; 112: 540-547.
27. Kagawa A, Azuma H, Akaike M, et al. Aspirin reduces apolipoprotein(a) (apo(a)) production in human hepatocytes by suppression of apo(a) gene transcription. J Biol Chem 1999; 274: 34111-34115.
28. Cushing GL, Gaubatz JW, Nava ML, et al. Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis 1989; 9: 593-603.
29. Akaike M, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002; 48: 1454-1459.
30. Discepolo W, Wun T, Berglund L. Lipoprotein(a) and thrombocytes: potential mechanisms underlying cardiovascular risk. Pathophysiol Haemost Thromb 2006; 35: 314-321.
31. Milionis HJ, Mikhailidis DP, Winder AF. Platelets and lipoprotein (a): a brief overview of their role in the pathogenesis of atherothrombosis. Platelets 1999; 10: 277-284.
32. Rand ML, Sangrar W, Hancock MA, et al. Apolipo-protein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscl Thromb Vasc Biol 1998; 18: 1393-1399.